LN-145: Investigational TIL Therapy for Cervical Cancer

Product Overview

Product Name	LN-145
Developer	Iovance Biotherapeutics
Therapy Type	Autologous Tumor-Infiltrating Lymphocyte (TIL) Therapy
Mechanism	Expansion of patient's own tumor-reactive T-cells (no genetic engineering)
Target Indication	Persistent, recurrent, or metastatic cervical cancer
Regulatory Status	Investigational Not FDA-approved
Clinical Development Phase	Phase 2 (C145-02 trial)
Relationship to Amtagvi	Same manufacturer (Iovance), similar TIL platform, different indication

What Is LN-145?

LN-145 is an investigational autologous TIL therapy product specifically developed for the treatment of advanced cervical cancer. Like all TIL therapies, LN-145 involves:

1. Tumor Tissue Harvest: Surgical biopsy or resection of cervical cancer tissue to obtain tumor-infiltrating lymphocytes
2. TIL Extraction & Expansion: In a specialized laboratory, T-cells that have naturally migrated into the tumor are isolated and multiplied to billions of cells over several weeks
3. Lymphodepletion: The patient receives a short course of chemotherapy to suppress their existing immune system
4. TIL Infusion: The expanded TILs are infused back into the patient
5. IL-2 Support: High-dose Interleukin-2 (IL-2) is administered to support TIL survival and activity

The LN-145 manufacturing process is similar to that used for Amtagvi, though optimized for cervical cancer tissue.

Clinical Development: The C145-02 Trial

LN-145 is being evaluated in the Phase 2 C145-02 clinical trial, which is designed to assess the safety and efficacy of LN-145 in patients with persistent, recurrent, or metastatic cervical cancer.

Trial Design

• Phase: Phase 2 (single-arm, open-label)
• Population: Adult patients with persistent, recurrent, or metastatic cervical cancer
• Prior Treatment: Patients must have progressed on at least one line of chemotherapy
• Primary Endpoint: Objective response rate (ORR)
• Secondary Endpoints: Duration of response (DOR), progression-free survival (PFS), overall survival (OS), safety

Preliminary Results

Early data from the C145-02 trial and related studies suggest:

• Objective Response Rate (ORR): Approximately 20-30% of heavily pre-treated patients achieved an objective response (partial or complete)
• Durable Responses: Some responders have maintained their response for over a year, though long-term data is still limited
• Safety Profile: Generally consistent with the known safety profile of TIL therapy (lymphodepletion effects, IL-2 toxicity), though cervical cancer-specific data is still being collected

LN-145 vs. Amtagvi: Key Differences

While both LN-145 and Amtagvi are TIL therapy products developed by Iovance Biotherapeutics, they have important differences:

Aspect	LN-145 Investigational	Amtagvi Approved
Indication	Cervical cancer	Advanced melanoma
Regulatory Status	Not FDA-approved; clinical trials only	FDA-approved (February 2024)
Clinical Evidence	Phase 2 trials; preliminary data	Phase 2 C-144-01 trial; FDA-reviewed
Response Rate	~20-30% (preliminary)	~31% (C-144-01 trial)
Manufacturing	Similar TIL platform, optimized for cervical tissue	Standardized TIL manufacturing process
Access	Clinical trial enrollment only	Commercially available at certified centers
Insurance Coverage	Varies; trial-specific	Generally covered for eligible patients

Eligibility for LN-145 Clinical Trials

Patients interested in LN-145 must meet specific eligibility criteria for the C145-02 trial or related studies. Common requirements include:

Disease Status

• Persistent, recurrent, or metastatic cervical cancer
• Progression after at least one line of chemotherapy
• Measurable disease on imaging (for response assessment)

Prior Treatments

• Documented failure of standard chemotherapy
• Some trials may require failure of additional therapies (e.g., immunotherapy)

Tumor Accessibility

• At least one cervical cancer lesion that can be safely biopsied or resected
• Adequate tissue yield expected for TIL extraction

Organ Function & Performance Status

• Adequate bone marrow, liver, kidney, and lung function
• ECOG performance status 0-1 (generally)
• No active infections or uncontrolled medical conditions

HPV Status

• Some trials may require confirmation of HPV-positive tumor (though not all)

Treatment Process for LN-145

The LN-145 treatment process is similar to the approved Amtagvi protocol:

1. Screening & Enrollment: Comprehensive evaluation to confirm trial eligibility
2. Tumor Harvest: Surgical biopsy or resection of cervical cancer tissue
3. Manufacturing (4-6 weeks): TILs are isolated and expanded at an Iovance-certified facility
4. Hospital Admission & Lymphodepletion: 3 days of cyclophosphamide and fludarabine
5. TIL Infusion: Single intravenous infusion of LN-145
6. IL-2 Administration: High-dose IL-2 with intensive monitoring (ICU or step-down unit)
7. Recovery & Follow-Up: Monitoring for response, side effects, and long-term outcomes

For detailed information on the TIL therapy process, see our step-by-step treatment guide →

Side Effects: What to Expect

The side effect profile of LN-145 is expected to be similar to Amtagvi, though cervical cancer-specific data is still limited:

• Lymphodepletion Effects: Low blood counts, infection risk, fatigue
• IL-2 Toxicity: Capillary leak syndrome, low blood pressure, organ dysfunction (requires ICU monitoring)
• Surgical Risks: Pain, infection, bleeding at biopsy/resection site
• Immune-Related Effects: Potential for autoimmune reactions

For detailed information on TIL therapy side effects, see our comprehensive side effects guide →

Unspoken Questions: What Patients Really Want to Know

"Is LN-145 the same as Amtagvi?"

No. While both are TIL therapy products developed by Iovance Biotherapeutics, they are evaluated for different cancer types and have different regulatory statuses. Amtagvi is FDA-approved for advanced melanoma, while LN-145 remains investigational for cervical cancer.

"When will LN-145 be approved?"

There is no guaranteed timeline for FDA approval. LN-145 must complete clinical trials and demonstrate sufficient safety and efficacy data before it can be considered for regulatory approval. This process can take several years, and approval is not guaranteed.

"Can I get LN-145 outside of a clinical trial?"

No. LN-145 is only available through registered clinical trials. It is not available as a standard treatment or through compassionate use programs at this time.

"What if I'm not eligible for the LN-145 trial?"

If you do not meet the eligibility criteria for the LN-145 trial, your oncologist can discuss other treatment options, which may include other immunotherapy approaches, targeted therapies, clinical trials of other investigational treatments, or palliative care.

"How much does LN-145 cost in a clinical trial?"

Costs vary by trial. Some trials cover the cost of the investigational product and trial-specific procedures, while patients may be responsible for standard care costs (hospitalization, imaging, etc.). It is essential to discuss financial considerations with the trial team and your insurance provider before enrollment.

Global Access & Trial Availability

LN-145 clinical trials are primarily being conducted in the United States, with some sites in other regions. Key considerations for international patients include:

• Travel Requirements: Patients typically need to travel to the trial site for screening, treatment, and follow-up visits
• Visa & Logistics: International patients must secure appropriate visas and arrange accommodation near the trial site
• Language & Communication: Trials are typically conducted in the local language; translation services may be available

Related Resources

Frequently Asked Questions